Unlock instant, AI-driven research and patent intelligence for your innovation.

Method of treating benign prostatic hyperplasia and other benign prostate conditions

A benign prostatic hyperplasia technology, applied in the fields of urinary system diseases, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as reducing the level of prostate specific antigen

Inactive Publication Date: 2006-10-18
李毅
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, isotretinoin or retinoic acid have not been used to treat benign prostatic hyperplasia, or to reduce PSA levels in benign prostatic disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] A patient presented with chronic progressive prostatic hypertrophy and decreased urine flow that began 20 years ago. Manual examination confirmed a palpable enlarged prostate, possibly due to postvasectomy prostatitis.

[0023] The patient received icotanil orally at 40 mg daily for 14 days during the initial treatment period. He then takes a maintenance dose of 40 mg every 5 days for about a year.

[0024] The patient's symptoms gradually improved. The palpable size of her prostate decreased and the PSA dropped from 4 to less than 1.

[0025] No adverse side effects were recorded except for dry lips and musculoskeletal soreness in some old wounds in the fingers and neck. The soreness subsided slowly after taking the maintenance dose. During this low maintenance dose, blood chemistry remained normal.

Embodiment 2

[0027] One patient had a previous history of urethritis and prostatitis due to sexually transmitted diseases. This patient's prostatic hypertrophy progressively worsened with decreased urine flow, urgency, and nocturia. PSA is 3, palpable prostatic hypertrophy.

[0028] The patient received icotanil 40 mg orally per day for 14 days. Then reduce the dose to 40 mg every 5 days for about 1 year.

[0029] The patient's symptoms gradually improved, and after 6 months, the PSA had dropped to less than 1. No adverse side effects caused by taking icotanil were observed.

Embodiment 3

[0031] One patient had a history of post-traumatic prostatitis from a bicycle accident in 1987. Especially after a long car trip, the patient's condition became chronic, requiring frequent antibiotics and steroids to suppress inflammation. The PSA is 5.

[0032] The patient took icotanil 40 mg daily for 14 days. The patient then took a maintenance dose of 40 mg every 5 days for about a year.

[0033] The patient's symptoms resolved rapidly after initial treatment and remained so during the maintenance period. PSA drops to less than 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for treating benign prostatic hyperplasia and reducing the level of prostate specific antigen (PSA) in benign prostatic diseases. The treatment method includes initial treatment of the patient, that is, the patient takes 13-cis retinoic acid orally for about 10 days to about 20 days at an initial dose of about 40 mg per day; and then maintains the patient, that is, during the maintenance period, the patient 13-cis retinoic acid is administered orally at a maintenance dose of about 40 mg about every 5-7 days.

Description

technical field [0001] The present invention relates to methods for treating benign prostatic hyperplasia and reducing the level of prostate specific antigen in benign prostatic disease. More specifically, the method utilizes 13-cis retinoic acid to effectively treat benign prostatic hyperplasia and reduce the level of prostate specific antigen in patients with benign prostatic disease. Background technique [0002] The three most common prostate health issues facing men and their families today are benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis. These diseases affect the prostate gland in different ways. Benign prostatic hyperplasia is the most common benign tumor (noncancerous enlarged prostate) in men and has a high incidence with age. The prostate increases in size within its sac, putting pressure on the urethra that passes through the sac, causing blockage of urine flow. Histologically identified, half of men have BPH by the age of 60, and the i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/47A61K9/14A61K9/16A61K9/20A61K9/48A61P13/08A61K31/203
CPCA61K31/203A61P13/08
Inventor L·迪安·帕克斯
Owner 李毅